|
KMID : 0191120220370140107
|
|
Journal of Korean Medical Science
2022 Volume.37 No. 14 p.107 ~ p.107
|
|
|
The Risk of Tuberculosis in Patients With Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab in Korea
|
|
Choi Myeong-Geun
Ye Byong-Duk
Yang Suk-Kyun
Shim Tae-Sun
Jo Kyung-Wook
Park Sang-Hyoung
|
|
|
Abstract
|
|
|
|
The present study investigated the risk of active tuberculosis in patients with inflammatory bowel disease (IBD) treated with vedolizumab or ustekinumab, in actual clinical settings in a country with an intermediate tuberculosis burden. The medical records of 238 patients with IBD who received vedolizumab or ustekinumab were retrospectively reviewed at a tertiary referral center in South Korea. All patients had ≥ 3 months of follow-up duration and underwent a latent tuberculosis infection screening test before initiation of the administration of these drugs. Of the 238 patients enrolled, 181 had Crohn’s disease, and 57 had ulcerative colitis. During the median 18.7 months of follow-up, active tuberculosis did not develop in any patient treated with vedolizumab or ustekinumab. Therefore, we concluded that the risk of tuberculosis appears to be low in patients with IBD treated with vedolizumab or ustekinumab in South Korea.
|
|
|
KEYWORD
|
|
|
Vedolizumab, Ustekinumab, Tuberculosis, Inflammatory Bowel Disease
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
    
|